Frontlight ResearchEarly access
WithdrawnPhase 2
Gentian Violet Treatment for Hidradenitis Suppurativa
Key facts
- Who runs it
- Wake Forest University Health Sciences
- Where
- Winston-Salem, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- Aug 2025
- Expected to end
- Dec 2026
- Type of study
- Interventional
- Treatments tested
- Gentian Violet
- Record updated
- 4 September 2025
- Why it stopped
- Drug company did not approve use of the drug, IRB never approved
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Patients must have active HS, be willing to undergo one application of HS, and agree to follow-up in one month
Who cannot take part
- Exclusion criteria include children, absent HS lesions at the time of clinic, and cognitive/physical impairments that would make them unable to assess quality of life factors of the survey
Where in United States
- Wake Forest School of MedicineWinston-Salem, United States
About the trial
What the trial wants to find out
This is a survey study being conducted to describe how subjects with Hidradenitis suppurativa (HS) respond to treatment with gentian violet. The study will rely primarily on qualitative survey responses and quantitative changes in skin appearance.
The group in the trial
- Gentian Violet TreatmentTreatment being tested
A single application of gentian violet will be topically applied to the site(s) of active HS involvement by a trained staff member. The sites will then be bandaged by staff and patients will be instructed about home maintenance procedures.
Treatment: Gentian Violet
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effects of Gentian Violet Treatment on Patients With Hidradenitis Suppurativa
- Record updated
- 4 September 2025